Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1410 and LB4330 Combination in Advanced Solid Tumors
NCT06468358Phase 2Recruiting
- Sponsor
- L&L Biopharma Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LB1410, LB4330 in pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma (CCA), colorectal cancer (CRC), ovarian cancer, fallopian tube cancer (PFTC), sponsored by L&L Biopharma Co., Ltd.. Started Jun 2024; status: recruiting.
02
Drugs
LB1410LB4330
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)cholangiocarcinoma (CCA)colorectal cancer (CRC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06468358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468358.